{"model":"gpt-5.6-terra","cadence_seconds":600,"rotation":[{"slug":"melanoma","name":"Melanoma","kind":"control"},{"slug":"nsclc","name":"NSCLC","kind":"active"},{"slug":"bladder","name":"Bladder","kind":"active"},{"slug":"pancreatic","name":"Pancreatic","kind":"active"},{"slug":"colorectal","name":"Colorectal","kind":"active"},{"slug":"renal","name":"Renal Cell","kind":"active"},{"slug":"head-neck","name":"Head & Neck","kind":"active"},{"slug":"breast","name":"Breast","kind":"active"},{"slug":"glioblastoma","name":"Glioblastoma","kind":"active"},{"slug":"prostate","name":"Prostate","kind":"active"},{"slug":"ovarian","name":"Ovarian","kind":"active"},{"slug":"cml","name":"CML","kind":"control"}],"current_cancer":"nsclc","current_visit":1,"current_status":"done","current_summary":"Phase 3 V940 NSCLC development is active; immunopeptidomics improves neoantigen selection, while presentation defects remain a hard gate.","next_cancer":"bladder","total_visits":5,"live":false,"ladder":{"leads":5,"candidates":0,"dossiers":0,"retired":0},"cancers_seen":3,"updated_at":"2026-08-19T21:02:40.572Z"}